Clinical Trial Update: REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) [Phase 3]

View source ↗

Summary

A Phase 3 trial (REZILIENT3) evaluating zipalertinib for advanced or metastatic EGFR exon 20 insertion non-small cell lung cancer is currently active but not re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Zipalertinib (Zipalertinib)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation | Phase 3 | Status: ACTIVE_NOT_RECRUITING